ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) Director Jeanne Thoma sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $71.53, for a total value of $71,530.00. Following the transaction, the director directly owned 26,762 shares in the company, valued at $1,914,285.86. The trade was a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Performance
Shares of NASDAQ ANIP traded up $0.21 during mid-day trading on Monday, reaching $70.40. 357,649 shares of the company were exchanged, compared to its average volume of 331,768. The company’s 50-day simple moving average is $76.97 and its 200-day simple moving average is $78.17. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.62 billion, a P/E ratio of 15.17 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $99.39.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its stake in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in ANI Pharmaceuticals in the second quarter valued at $76,000. State of Wyoming bought a new position in ANI Pharmaceuticals during the 2nd quarter worth $86,000. Finally, Kingdom Financial Group LLC. acquired a new position in ANI Pharmaceuticals during the 4th quarter worth about $141,000. Institutional investors own 76.05% of the company’s stock.
Analyst Upgrades and Downgrades
ANIP has been the topic of several recent research reports. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Guggenheim reduced their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Canaccord Genuity Group lowered their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Finally, Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $105.57.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.
ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.
See Also
- Five stocks we like better than ANI Pharmaceuticals
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in ANI Pharmaceuticals Right Now?
Before you consider ANI Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ANI Pharmaceuticals wasn’t on the list.
While ANI Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
